New drug combo targets brain tumor fuel in early trial

NCT ID NCT03343197

Completed Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested two experimental drugs, AG-120 and AG-881, in 49 adults with a recurrent, slow-growing brain tumor (low grade glioma) that has a specific IDH1 gene mutation. The goal was to see if these drugs could lower a substance called 2-HG in the tumor tissue before surgery. The study focused on safety and how the drugs work in the body, not on curing the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma low grade glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

United States, California

Los Angeles, California, 90024, United States
United States, California

San Francisco, California, 94143, United States
United States, Massachusetts

Boston, Massachusetts, 02215, United States
United States, New York

New York, New York, 10065, United States
United States, North Carolina

Durham, North Carolina, 27710, United States
United States, Texas

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.